FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide

WHY IT MATTERS

This approval under the National Priority Voucher Program suggests semaglutide may address weight management in a rare disease population, though the article does not specify which rare condition qualifies for this higher dose.

The FDA approved a new, stronger version of the weight loss drug Wegovy (semaglutide) at 7.2 mg. This higher dose is intended for adults who need help losing weight and keeping it off long-term. This approval was granted under a special FDA program that prioritizes treatments for rare diseases.

The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection for weight loss and long-term maintenance of weight loss for certain adult patients.

ASK YOUR DOCTOR

If you have a rare disease involving weight management challenges, ask your doctor whether this higher-dose semaglutide might be appropriate for you and whether you meet eligibility criteria.